舒更葡糖缩短心脏手术后拔管时间的疗效与安全性:单中心随机安慰剂对照试验
该单中心、随机、双盲、安慰剂对照试验纳入90例择期主动脉瓣置换(AVR)和/或冠状动脉旁路移植(CABG)手术患者,术后入ICU时随机接受舒更葡糖2 mg/kg或安慰剂。主要终点为从给药至拔管的时间,舒更葡糖组中位126.0分钟(IQR 84.0-274.0),安慰剂组219.0分钟(IQR 121.0-323.0),均值差72.8分钟(95%CI 1.5-144.1,P=0.01)。两组在负力吸气、肺活量、术后血制品需求、心律失常、ICU住院时间及住院时间方面无差异,均无严重不良事件。作者认为该结果可缩短拔管时间约1小时,但需更大规模试验确认。
要点
- 心脏手术后入ICU给予舒更葡糖2 mg/kg,拔管时间中位数126.0分钟 vs 安慰剂219.0分钟,均值差72.8分钟(95%CI 1.5-144.1,P=0.01)。
- 两组负力吸气(舒更葡糖组均值33.79 cm H2O [SD 8.39] vs 安慰剂组-31.11 cm H2O [SD 7.17])和肺活量(中位1.1 L [IQR 0.9-1.3] vs 1.0 L [IQR 0.9-1.2])无差异。
- 两组术后血制品需求、心律失常、ICU住院时间及住院时间均无差异。
- 两组均无严重不良事件。
- 作者认为该试验显示舒更葡糖使拔管时间缩短约1小时,但可能需要更大规模试验确认这些发现并确定临床意义。
适用人群与场景
- 择期主动脉瓣置换(AVR)和/或冠状动脉旁路移植(CABG)手术后收入心胸外科ICU的患者(n=90)。
- 共68例行CABG,13例行AVR,9例行AVR联合CABG。
处置流程与药物剂量
- 患者到达ICU后随机接受舒更葡糖2 mg/kg或安慰剂。
- 主要终点为从研究药物给药至拔管的时间。
研究设计与关键结果
- 研究类型:单中心、随机、双盲、安慰剂对照试验;样本量90例(每组45例);人群为择期AVR和/或CABG手术后患者;干预为入ICU后舒更葡糖2 mg/kg,对照为安慰剂。
- 主要终点:拔管时间中位数舒更葡糖组126.0分钟(IQR 84.0-274.0)vs 安慰剂组219.0分钟(IQR 121.0-323.0),均值差72.8分钟(95%CI 1.5-144.1),P=0.01。
- 负力吸气:舒更葡糖组均值33.79 cm H2O(SD 8.39)vs 安慰剂组-31.11 cm H2O(SD 7.17),无差异。
- 肺活量:舒更葡糖组中位1.1 L(IQR 0.9-1.3)vs 安慰剂组1.0 L(IQR 0.9-1.2),无差异。
- 术后血制品需求、心律失常、ICU住院时间及住院时间两组无差异。
- 两组均无严重不良事件。
证据类型、等级与局限
- 证据类型:单中心、随机、双盲、安慰剂对照试验。
- 局限:作者指出可能需要更大规模试验确认这些发现并确定临床意义。
对床旁实践的改变
- 作者认为该试验显示心脏手术后给予舒更葡糖使拔管时间缩短约1小时。
- 作者指出可能需要更大规模试验确认这些发现并确定临床意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Residual neuromuscular blockade (NMB) is an important and modifiable factor associated with prolonged mechanical ventilation after cardiac surgery. Studies evaluating the use of sugammadex for residual NMB reversal in the post-cardiac surgery ICU setting are lacking. We conducted a randomized trial to determine the efficacy of sugammadex in reducing time to extubation in patients admitted to the ICU after cardiac surgery.
DESIGN: Single-center, randomized, double-blind, placebo-controlled trial.
SETTING: University-based cardiothoracic ICU.
SUBJECTS: Patients (n = 90) undergoing elective aortic valve replacement (AVR) and/or coronary artery bypass grafting (CABG) surgery.
INTERVENTIONS: Participants were randomized to receive either sugammadex (2 mg/kg) or placebo after arrival to the ICU.
MEASUREMENTS AND MAIN RESULTS: The primary study endpoint was time from study drug administration to extubation. Of the 90 patients included in the study (45 in each group), a total of 68 patients underwent CABG, 13 AVR, and nine combined AVR and CABG. Baseline characteristics and intraoperative anesthetic medications were comparable between groups. Patients in sugammadex group had reduced time to extubation compared with the placebo group (median [interquartile range (IQR)]-sugammadex group: 126.0 min [84.0-274.0 min] vs placebo: 219.0 min [121.0-323.0 min]; difference in means [95% CI], 72.8 [1.5-144.1 min]; p = 0.01. There were no differences in negative inspiratory force (mean [sd]-sugammadex group: 33.79 cm H2O [8.39 cm H2O] vs placebo: -31.11 cm H2O [7.17 cm H2O]) and vital capacity (median [IQR]-sugammadex group: 1.1 L [0.9-1.3 L] vs placebo: 1.0 L [0.9-1.2 L]). There were no differences between groups in postoperative blood product requirement, dysrhythmias, length of ICU, or hospital stay. There were no serious adverse events in either group.
CONCLUSIONS: This randomized trial showed that the administration of sugammadex after cardiac surgery decreased time to extubation by approximately 1 hour. Larger trials may be required to confirm these findings and determine the clinical implications.
参考来源
- Bardia A, Treggiari MM, Dai F, et al. Efficacy and Safety of Sugammadex to Shorten Time-to-Extubation Following Cardiac Surgery: A Single-Center Randomized Placebo-Controlled Trial. Crit Care Explor. 2022. PMID: 36601562. doi:10.1097/CCE.0000000000000821
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。